Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 17;13:829366. doi: 10.3389/fimmu.2022.829366

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yang, Li, Piao, Liu, Wei, Sang, Zhang and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Survival analysis according to different treatment strategies. Patients treated with asparaginase-based chemotherapy had significantly better overall survival (A) and progression-free survival (B) than those treated with anthracycline-based regimens. Out of patients with stage I-II disease who were treated with anthracyline-based chemotherapy, patients who were CD56 negative had significantly inferior overall survival (C) and progression-free survival (D) than those CD56 positive ones. Out of patients with stage I-II disease who were treated with asparaginase–based chemotherapy, the expression status of CD56 was not related with overall survival (E) and progression-free survival (F).